登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600103 证券简称：青山纸业 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 注："本报告期"指本季度初至本季度末3个月期间，下同。 （二）非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 （三）主要会计数据、财务指标发生变动的情况、原因 （一）主要会计 ...

Core Viewpoint - The company reported a strong revenue growth in Q3 2025, but net profit declined significantly due to a one-time patent payment, indicating underlying business strength when excluding this impact [4][5]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 3.453 billion yuan, a year-on-year increase of 8.52%, while net profit attributable to shareholders was 211 million yuan, down 17.36% [4]. - In Q3 2025, the company recorded a revenue of 1.190 billion yuan, reflecting a year-on-year growth of 13.40%, but net profit dropped by 47.55% to 30 million yuan due to a one-time payment of 19 million USD (approximately 136 million yuan) related to a patent settlement [4][5]. Business Segments - The Continuous Glucose Monitoring (CGM) business has become a key driver of growth, with the company on track to meet its annual sales targets. A differentiated strategy is employed, focusing on cost-effective first-generation products and high-end second-generation products [6]. - The domestic BGM business continues to show steady growth, while the overseas market is seeing positive developments, particularly in Europe and the Middle East, where CGM products are gaining insurance coverage [6]. Market Challenges - The company faces short-term uncertainties due to a patent lawsuit initiated by Abbott in Europe, which affects the sales of the first-generation CGM products in certain countries. However, the second-generation products are not impacted, and the company is actively evaluating promotional strategies for these products in Europe [7]. - The overseas subsidiaries, particularly Trividia, are showing continuous revenue growth, and there is a noticeable improvement in the operations of PTS. The company has established a global sales network and brand resources, indicating potential for successful international expansion [8].

三诺生物 20251024 摘要 三诺生物三季度归母净利润受 Trividia 与罗氏交叉专利授权费用影响， 若排除该费用，归母净利润同比增长超 82%。前三季度整体同比增长超 12%，显示公司核心业务稳健增长。 国内传统业务单季度收入增长超 10%，CJM 业务收入同比增长超 80% 并持续减亏，海外市场 Trividia 市场份额提升，收入环比增长，PTS 业 务收入和利润同比增长，整体业务表现良好。 CGM 产品前三季度海外销售额约 8,000 万元，三季度订单增长，毛利 率超 50%。但因雅培专利诉讼，部分欧洲国家供货受限，预计上诉结果 和二代产品策略将决定未来增长。 雅培提出 633 专利诉讼导致三诺生物部分欧洲国家一代 CGM 产品暂停 销售，公司正积极上诉并评估二代产品投放策略，以应对潜在的法律挑 战。 三诺生物计划在美国推出二代 CGM 产品，预计 2026 年上半年进行小 型预临床，下半年启动主临床，总费用预算约为 2000 万美元，不受欧 洲诉讼直接影响。 Q&A 三诺生物 2025 年三季度的主要经营表现和亮点是什么？ 三诺生物在 2025 年三季度实现营业收入 11.9 亿元，同比增长 ...

债券代码：123090 债券简称：三诺转债 证券代码：300298 证券简称：三诺生物 三诺生物传感股份有限公司投资者关系活动记录表 编号：2025-10-01 | 投资者关系活动 | 特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他（请文字说明其他活动内容） 华泰证券：代雯、高鹏、杨昌源；华安证券：李婵；兴业证券：董晓洁； | | | 天风证券：周海涛；中信证券：沈睦钧；中信建投证券：华冉；中金公 | | | 司：刘雅馨；国盛证券：杨芳、王震；华创证券：陈俊威；国金证券：何 | | | 冠洲；申万宏源证券：陈烨远；东吴证券：向潇、王美麒；中国银河证 | | 参与单位名称及 | 券：程培、孟熙；光大证券：吴佳青；民生证券：朱凤萍；信达医药：曹 | | 人员姓名 | 佳琳、唐爱金；国泰海通证券：孟陆、谈嘉程；华金证券：苏雪儿；华福 | | | 证券：王艳；长江证券：徐晓欣；睿远基金：傅鹏博；华夏基金：常黎 | | | 曼、谢子情；西部证券：陆伏崴、吕晔、孙阿敏；泰信基金：曲奕丞、李 | | ...

Core Viewpoint - The lawsuit involving BeiGene and Pharmacyclics has been voluntarily withdrawn, resulting in no negative impact on the company's operations or product development in the U.S. market [2][5][4]. Group 1: Lawsuit Details - On June 13, 2023, Pharmacyclics LLC filed a lawsuit against BeiGene and its subsidiary BeOne Medicines USA, claiming patent infringement related to the product 百悦泽? [3]. - The patent in question is U.S. Patent No. 11,672,803, which was granted to Pharmacyclics on the same day the lawsuit was filed [3]. - The court has agreed to pause the infringement lawsuit pending the outcome of a Patent Trial and Appeal Board (PTAB) review, which is expected to conclude by November 1, 2023 [3]. Group 2: Impact on the Company - The lawsuit has not adversely affected the research and sales of 百悦泽? in the U.S. market, nor has it significantly impacted the company's overall operations [5]. - The company maintains confidence in its intellectual property related to 百悦泽? and plans to continue developing innovative cancer treatment solutions [2][5].

Core Viewpoint - Pharmacyclics LLC has decided not to appeal the final written decision from the USPTO regarding the patent dispute with BeiGene, leading to the voluntary withdrawal of the lawsuit by both parties [1][4]. Group 1: Legal Proceedings - On June 13, 2023, Pharmacyclics filed a lawsuit against BeiGene and its subsidiary BeOne Medicines USA, claiming that the product Brukinsa infringed on its US patent No. 11,672,803 [4]. - The court agreed to suspend the infringement lawsuit pending the outcome of BeiGene's application for a post-grant review (PGR) of the '803 patent, which is due by November 1, 2023 [4]. - On April 29, 2025, the USPTO declared the '803 patent invalid, and Pharmacyclics had the option to appeal this decision [4][5]. Group 2: Financial Performance - In the first half of 2025, BeiGene reported total revenue of 17.518 billion yuan, a year-on-year increase of 46.0%, and achieved a net profit of 450 million yuan, compared to a loss of 2.877 billion yuan in the same period last year [7]. - The majority of BeiGene's revenue came from international markets, with overseas sales of Brukinsa reaching 11.335 billion yuan, accounting for 65.3% of total revenue, while sales in China were 1.192 billion yuan [7]. Group 3: Historical Financials - From 2017 to 2020, BeiGene experienced significant net losses, with figures of 982 million yuan, 4.747 billion yuan, 6.915 billion yuan, and 11.384 billion yuan respectively [5]. - The company continued to incur losses from 2021 to 2023, with net losses of 9.748 billion yuan, 13.642 billion yuan, and 6.716 billion yuan [5].

Core Viewpoint - The lawsuit against Yushu Technology by Luweimei Company regarding patent infringement has been dismissed by the Hangzhou Intermediate People's Court, allowing Yushu Technology to proceed with its IPO plans without legal hindrance [1][11]. Group 1: Company Overview - Yushu Technology is an AI unicorn valued at over 10 billion RMB and is currently in the IPO guidance phase [2][13]. - The company has completed a C-round financing led by major investors including Tencent and Alibaba, with a pre-investment valuation exceeding 10 billion RMB [13]. Group 2: Legal Proceedings - Luweimei Company, which is not a direct competitor of Yushu Technology, claimed that Yushu's "Go2 Robot Dog" infringed on its patent for an "electronic dog" [3][6]. - The court ruled that Luweimei's claims lacked sufficient evidence, as they did not provide physical evidence for comparison, leading to the dismissal of all their requests [8][9][11]. Group 3: Patent Details - The patent in question, numbered ZL201610396363.0, was originally held by Zhejiang Jianlin Electronics and has changed ownership multiple times, with Luweimei being the current holder [3][4]. - Yushu Technology has reportedly filed a request for the invalidation of the aforementioned patent with the National Intellectual Property Administration [4]. Group 4: Industry Context - Patent litigation has become a common challenge for companies during the IPO process, often used as a strategic maneuver by competitors or non-industry entities [20][21]. - The outcome of such lawsuits can significantly impact a company's IPO timeline and valuation, making knowledge of intellectual property compliance crucial for companies preparing to go public [20][21].

Group 1 - Company Bawei Storage recently disclosed information regarding patent litigation, where the plaintiff, Yuan Yuzhi Technology (Shenzhen) Co., Ltd., filed two lawsuits for patent infringement. Bawei Storage claims it lacks standing and argues non-infringement [1] - The court has allowed the plaintiff to withdraw the lawsuit, but another company, Emter Storage Technology (Shenzhen) Co., Ltd., has filed a new lawsuit on the same matter, which is currently accepted by the court but has not yet been heard [1] - The total amount involved in the new lawsuit from Emter Storage is approximately RMB 1,216,850, which includes legal fees and litigation costs for both cases [1] Group 2 - Bawei Storage believes that the litigation will not affect its ability to supply customers, as the amount in question is relatively low, and the impact on current and future profits is expected to be minimal [1] - The company emphasizes its commitment to independent innovation and intellectual property protection, holding a total of 393 domestic and international patents, including 171 invention patents, as of June 30, 2025 [1] - In the ongoing patent licensing negotiations, the company adheres to the FRAND principle, and the patent in question is set to expire on November 27, 2026. The company has also initiated a request for invalidation of the patent with the National Intellectual Property Administration [2]

深圳佰维存储科技股份有限公司发布公告。此前，原告元预知技术（深圳）有限公司就两起侵犯发明专 利权纠纷起诉佰维存储，公司主张其不具备诉讼主体资格并抗辩不构成侵权，近日原告撤诉。但埃姆梯 尔存储技术（深圳）有限公司就同一事项再次起诉，目前法院已立案未开庭。本次涉案金额两案件合计 121.685万元。因公司遵守FRAND原则、无明显过错且涉案专利即将到期，预计诉讼对公司供货能力和 利润影响较小。公司已提起专利无效宣告请求，将积极应诉并及时披露进展，提醒投资者注意风险。 ...

Financial Data and Key Metrics Changes - The company reported a guidance for Firdapse revenue in 2025 of $355 million to $360 million, with year-to-date trends tracking positively against these assumptions [28] - The addressable market for Firdapse is estimated at over $1 billion, with confidence in reaching this target due to recent increases in maximum dosage from 80 mg to 100 mg [30][31] - The company anticipates a revenue of $100 million to $110 million for GammaRay in 2025, with an addressable market of $1.2 billion [52] Business Line Data and Key Metrics Changes - Firdapse has a market penetration of approximately 30% in the idiopathic LEMS segment, with an addressable market of about 1,700 to 2,000 patients [9] - The cancer-associated LEMS segment has a market penetration of only about 10%, with an addressable market of $600 million [18] - GammaRay has been successful in capturing market share, with 45% of patients coming from prednisone, 45% from Emflaza, and 10% being naive patients [45] Market Data and Key Metrics Changes - The company has established a partnership with Quest Diagnostics for frictionless testing, which is expected to enhance patient diagnosis and treatment pathways [14] - The NCCN guidelines have been updated favorably for LEMS patients, which is anticipated to improve market access and treatment adherence [20] Company Strategy and Development Direction - The company is focused on a "buy and build" strategy, seeking opportunities in the market while managing commercial and regulatory risks [3] - There is a strong emphasis on lifecycle management of existing products and potential acquisitions to drive growth [5] - The company aims to maintain a strong balance sheet while exploring business development opportunities in CNS and other therapeutic areas [90] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in both idiopathic and cancer-associated LEMS markets, particularly with improved diagnostic capabilities [21] - The company is preparing for potential challenges in the market, including competition from generics and the need for effective patient education [56] - Management highlighted the importance of building credibility with patient advocacy groups and adapting to the evolving landscape of gene therapy [87] Other Important Information - The company has a dedicated sales force for both Firdapse and GammaRay, which is expected to enhance market penetration and patient engagement [83] - There is an upcoming Markman hearing related to patent litigation, which could influence the company's market position and exclusivity [36] Q&A Session Summary Question: What are the assumptions behind the 2025 guidance for Firdapse? - The guidance is based on an increase in maximum dosage and a reassigned sales force dedicated to Firdapse, which is expected to drive patient uptake [28][29] Question: How does the company plan to address the discontinuation rate of Firdapse? - Management noted that the primary reason for discontinuation is patient mortality, but they are implementing a titration schedule to improve patient retention [22][23] Question: What is the strategy for GammaRay in a competitive market? - The company plans to position GammaRay slightly below the branded Emflaza to ensure market access and capitalize on existing patient dissatisfaction with current therapies [41][42] Question: How does the company view the impact of generics on Fycompa? - Management acknowledged that while prescription volumes may remain stable, dollar share is expected to decline as generics enter the market [78][79] Question: What are the key achievements the company aims for in the next year? - The company aims to achieve full enrollment in the SUMMIT study and advance its cancer LEMS initiative [93]